Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Astellas Pharma and Roche Diabetes Care Japan have signed an agreement to develop and commercialise the latter’s Accu-Chek Guide Me blood glucose monitoring system as a combined medical product with BlueStar.

​​Magtivio, a magnetic bead manufacturer from The Netherlands announces a distribution agreement with Premedical Lab from Beijing, China, a professional laboratory products distribution company in the life sciences arena.

Todos Medical said on Tuesday that it has signed a letter of intent with Acumen Diagnostics of Singapore under which its Provista Diagnostics subsidiary will offer Acumen's AcuSept sepsis test in the US.

QuidelOrtho Corporation celebrates Women’s History Month by announcing that the QuidelOrtho Women’s Leadership Network (QWLN) has been formed, creating an enhanced network with 14 global leaders supporting 16 chapters around the world.

On March 28, Sinopharm (Shanghai) Medical Device Supply Chain Co., Ltd. and Calibra signed a strategic cooperation agreement in Hangzhou, China.

DiaSorin said on Monday that its full-year 2022 revenues grew 10 percent year over year on "solid performance" across all its businesses.

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the AmoyDx Pan Lung Cancer PCR Panel as a companion diagnostic to direct the use of Eli Lilly's Retevmo (selpercatinib) in RET fusion-positive non-small cell lung cancer.

On March 27, 2023, MGI and Fujian Berry Oncology Co., Ltd. signed the strategic cooperation agreement.

According to Kalorama Information, the U.S. IVD market reached $53 billion in 2022, or approximately 40% to 45% of the global market. Projected growth is 2.4% annually on average through 2027.

Quest Diagnostics has introduced two Post-COVID-19 panels for consumers that offer information about lingering health issues associated with previous COVID-19 virus infections.